Press releases
- Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma
- Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis
- Adicet Bio to Participate in a Fireside Chat at the 2024 Jefferies Healthcare Conference
- Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates
- Adicet Bio Announces Poster Presentation of ADI-270 Preclinical Data at the 2024 European Hematology Association (EHA) Hybrid Congress
- Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference
- Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
- Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
- Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | 1.07 |
Low | 1.07 |
Bid | -- |
Offer | -- |
Previous close | 1.07 |
Average volume | 4.02k |
---|---|
Shares outstanding | 82.17m |
Free float | 80.86m |
P/E (TTM) | -- |
Market cap | 89.57m USD |
EPS (TTM) | -2.95 USD |
Data delayed at least 20 minutes, as of Jul 03 2024 16:39 BST.
More ▼